# Cingulate Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Cingulate Inc.). ## Overview Cingulate Inc. is a clinical-stage pharmaceutical company developing differentiated prescription therapies, with its lead program CTx-1301 aimed at ADHD. The company is focused on advancing its pipeline through clinical development, regulatory filing, and eventual commercialization via partnerships or outsourced sales infrastructure. ## Products & services • CTx-1301 ADHD product candidate • CTx-1302 (dextroamphetamine) ADHD program • CTx-2103 clinical and manufacturing development • Licensing and collaboration opportunities for pipeline assets • Commercialization services via Indegene partnership - **Lead drug candidate development** (70%) — Clinical development, manufacturing, and regulatory work for CTx-1301 and related pipeline assets. - **Pipeline expansion and in-licensing** (15%) — Evaluation of new products, product candidates, and acquisitions to broaden the portfolio. - **Commercialization partnerships** (10%) — Potential licensing and fee-for-service commercialization support for approved products. - **Grant-funded development programs** (5%) — Externally funded clinical and manufacturing work, including CTx-2103 support. - CTx-1301, the lead investigational ADHD therapy - CTx-1302 (dextroamphetamine), second ADHD candidate - CTx-2103 clinical and manufacturing development program - Out-licensing and strategic partnership arrangements - Commercialization support through Indegene services ## Customers Cingulate does not yet sell commercial products, so its near-term counterparties are primarily clinical research organizations, manufacturers, regulators, and potential licensing partners. If approved, its end customers would be physicians, patients, and payers in the ADHD market, with commercialization potentially handled through partners rather than a large internal sales force. - **Pharmaceutical licensing partners** (primary) — Companies that may license CTx-1301 in the U.S. or internationally to commercialize the asset. - **Clinical development vendors** (primary) — CROs, investigators, and manufacturers that provide trial execution, supply, and testing services. - **Regulatory agencies** (primary) — FDA and comparable authorities that review the NDA and determine approval timing. - **Future ADHD prescribers and patients** (emerging) — Physicians and patients who would use the product if approved, driving eventual product demand. - Clinical trial vendors and CROs supporting development work - FDA and other regulators reviewing the NDA and clinical data - Potential pharmaceutical partners licensing CTx-1301 - Commercialization service providers such as Indegene - Future physicians, patients, and payers for ADHD therapies ## Geography Cingulate is headquartered in the United States and its current development, regulatory, and commercialization planning is centered there. The company also states it may seek international licensing for CTx-1301, but it has not disclosed meaningful country revenue because it has not generated product sales. - United States is the core operating and regulatory market - FDA approval timing is critical to U.S. commercialization - Indegene services are tied to U.S. commercialization planning - International licensing is a potential future expansion path - No disclosed product revenue by country to date ## Strategy Cingulate’s strategy is to complete development of CTx-1301, file the NDA, and secure a pharmaceutical partner or outsourced commercialization model. It is also trying to broaden the pipeline through in-licensing, acquisitions, and grant- or partner-supported development to reduce dependence on a single asset. - **File the NDA for CTx-1301** (short-term) — Regulatory submission is the key milestone needed to move the lead asset toward approval and value creation. - **Secure a strategic pharmaceutical partnership** (short-term) — A partner can provide commercialization reach and reduce the need for Cingulate to build costly sales infrastructure. - **Fund pipeline and commercialization needs** (short-term) — The company needs additional capital to continue development and support launch activities if approval is obtained. - **Broaden the product pipeline** (medium-term) — Adding assets through in-licensing or acquisition can diversify risk beyond a single lead program. - Advance CTx-1301 to NDA filing and potential approval - Secure a U.S. and/or international licensing partner - Use outsourced commercialization instead of building a large sales force - Expand the pipeline through in-licensing and acquisitions - Raise additional capital to fund development and commercialization ## Risks Cingulate is a pre-revenue clinical-stage company, so its business depends on successful trials, regulatory approval, and access to capital. The company also faces execution risk around manufacturing, commercialization outsourcing, and partner selection, while broader pharmaceutical risks include patent disputes, FDA delays, and inability to retain key personnel. - **Going-concern and financing risk** [critical] — The company has no product revenue and expects to need additional capital to fund operations and commercialization. - **Clinical and regulatory failure risk** [high] — CTx-1301 and other candidates may not achieve successful trial outcomes or FDA approval. - **Commercialization execution risk** [high] — The company may rely on partners or outsourced providers for marketing, sales, market access, and distribution. - **Manufacturing and supply chain risk** [medium] — Clinical supply and commercial-scale manufacturing timing can affect trial progress and launch readiness. - **Key personnel retention risk** [medium] — A small development-stage company depends heavily on a limited management and scientific team. - No product revenue yet, so survival depends on external financing - CTx-1301 may fail in trials or not receive FDA approval - Commercialization depends on partner execution or outsourced services - Manufacturing and clinical supply timing can delay development - Key-person and IP litigation risks are material for a small biotech ## Accounting Cingulate’s accounting is dominated by R&D expense recognition, stock-based and financing-related items, and going-concern judgments. Because it is pre-revenue, the timing of clinical vendor invoices, grant funding, and any future collaboration or license payments can materially affect quarterly results and liquidity disclosures. - **Research and development expense accruals** — Affects operating loss comparability quarter to quarter - **Going-concern assessment** — Important for liquidity and financial statement interpretation - **Grant accounting and contingent royalty obligation** — Affects cash flow, liabilities, and future commercialization economics - **Future collaboration and license revenue recognition** — Could materially change reported revenue once commercialization begins - R&D costs are expensed as incurred, affecting quarterly loss timing - Clinical vendor accruals depend on progress-based estimates - Grant funds for CTx-2103 may affect liquidity and related disclosures - Future license or collaboration revenue would depend on contract terms - Going-concern assessment is a key disclosure judgment --- *Last updated: 2026-04-28T19:57:53.729917+00:00*